Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition

globenewswire.com
JNJ Johnson & Johnson is mentioned as a leading company in the NMIBC market, indicating its involvement and potential impact on market dynamics and competition. MRK Merck & Co Inc is identified as a leading company in the NMIBC market, suggesting its significant role in the development and distribution of therapies within this sector. IBRX ImmunityBio Inc. received FDA approval for ANKTIVA, an innovative immunotherapy for BCG-unresponsive NMIBC patients, indicating a strong positive development and market potential. AZN AstraZeneca plc is listed as one of the leading companies spearheading innovation in the NMIBC market, highlighting its competitive position and contribution to the sector.

Non-Muscle Invasive Bladder Cancer (NMIBC) Market to Grow by $1 Billion During 2026-2030 - Johnson & Johnson, Janssen Research & Development, and Merck & Co. Lead the Competition Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Non-Muscle Invasive Bladder Cancer Market Report 2026" has been added to ResearchAndMarkets.com's offering.

The non-muscle invasive bladder cancer (NMIBC) market size has experienced robust growth, increasing from $3.66 billion in 2025 to an anticipated $4.82 billion by 2030. This expansion is driven by factors such as a rise in early diagnosis, enhanced use of transurethral resection, and increased adoption of immunotherapy and chemotherapy. Improvements in hospital pharmacy infrastructure and the development of online and retail pharmacy channels have also contributed significantly.

Personalized medicine is playing a crucial role in steering NMIBC market growth. This approach, which tailors treatment plans to an individual's genetic makeup and lifestyle, is facilitated by advancing genomic research and enhanced diagnostic tools. Recent data from the Personalized Medicine Coalition indicated that the FDA approved 16 new personalized treatments for rare diseases in 2023, illustrating strong year-on-year growth.

Corporate developments continue to shape the NMIBC landscape. ImmunityBio Inc. received FDA approval for ANKTIVA (N-803) in March 2024 for BCG-unresponsive patients, highlighting the importance of innovative immunotherapies. ANKTIVA, an IL-15 agonist, stimulates immune cells to attack cancerous cells. Additionally, a partnership between Ferring Pharmaceuticals and SK Pharmteco aims to bolster the production of Adstiladrin, a gene therapy to treat high-risk NMIBC.

The competitive landscape is rich with leading companies like Johnson & Johnson, Merck & Co Inc, AstraZeneca plc, and many others spearheading innovation and driving market dynamics. These companies are pivotal in the development and distribution of effective therapies and are crucial to market competitiveness.

In regional context, North America led the market in 2025, but Asia-Pacific is forecasted to exhibit the fastest growth through the next decade. Global market coverage spans across developed and emerging economies, inclusive of major players in Western Europe, Eastern Europe, and South America.

Reasons to Purchase:

Report Scope:

Key Attributes

The companies featured in this Non-Muscle Invasive Bladder Cancer market report include:

For more information about this report visit https://www.researchandmarkets.com/r/5lfrn7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment